Kizhake Kurian, MD
Cardiovascular Disease · Palm Coast, FLNPI 1427082486
Payments from drug & device makers
Across 375 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$761
- Novartis$670
- Johnson & Johnson$669
- Boehringer Ingelheim$632
- Cordis US CORP.$534
- Amgen$503
- plus $4K from 30 others
What the payments were for
- Food & beverage$7,667100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 88 | $761 |
| Novartis | 37 | $670 |
| Johnson & Johnson | 34 | $669 |
| Boehringer Ingelheim | 29 | $632 |
| Cordis US CORP. | 21 | $534 |
| Amgen | 26 | $503 |
| Cvrx, Inc. | 13 | $490 |
| E.r. Squibb & Sons, L.L.C. | 25 | $422 |
| Shockwave Medical, Inc | 5 | $274 |
| Boston Scientific | 10 | $273 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $219 |
| AstraZeneca | 8 | $207 |
| Inari Medical, Inc. | 1 | $199 |
| Novo Nordisk | 4 | $164 |
| Cardiovascular Systems Inc. | 8 | $161 |
| Terumo Medical Corporation | 2 | $145 |
| Sanofi-aventis U.S. LLC | 6 | $142 |
| Impulse Dynamics (USA) Inc. | 2 | $133 |
| Alnylam Pharmaceuticals Inc. | 5 | $131 |
| Penumbra, Inc. | 2 | $125 |
| Merck | 5 | $99 |
| Kestra Medical Technology Services, Inc. | 4 | $96 |
| Livanova USA, Inc. | 1 | $84 |
| Philips North America LLC | 3 | $76 |
| Angiodynamics, Inc. | 2 | $67 |
| Medicomp Inc | 2 | $61 |
| Abbott | 4 | $61 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Irhythm Technologies, Inc. | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Bayer | 2 | $46 |
| Pfizer | 1 | $22 |
| Cardinal Health 200 LLC | 1 | $20 |
| Vital Connect, Inc | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| ZOLL Circulation Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$199
- CT THROMBECTOMY SYSTEM KIT$199
- XARELTO$150
- Vascular Lithotripsy$148
- NAGARE$122
- RESOLUTE ONYX$121
- Indigo System$115
- Watchman$110
- Repatha$102
- JARDIANCE$100
- Barostim Neo System$100
How this compares
$7,690 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 231 | $304,324 |
| XareltoRivaroxaban | 133 | $159,122 |
| EntrestoSacubitril/Valsartan | 78 | $96,447 |
| FarxigaDapagliflozin Propanediol | 30 | $35,978 |
| JardianceEmpagliflozin | 32 | $35,735 |
| BrilintaTicagrelor | 37 | $33,094 |
| Repatha SureclickEvolocumab | 19 | $21,784 |
| MultaqDronedarone Hcl | 17 | $20,796 |
| Repatha SyringeEvolocumab | 20 | $15,373 |
| OzempicSemaglutide | 14 | $14,414 |
| Ranolazine ErRanolazine | 58 | $5,276 |
| Metoprolol Succinate | 274 | $3,887 |
| Digoxin | 80 | $2,125 |
| Prasugrel Hcl | 18 | $1,818 |
| Carvedilol | 183 | $1,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $22 | $304,324231 claims |
| Johnson & JohnsonXarelto | $669 | $159,122133 claims |
| NovartisEntresto | $670 | $96,44778 claims |
| AstraZenecaFarxiga, Brilinta | $207 | $69,07267 claims |
| Boehringer IngelheimJardiance | $632 | $35,73532 claims |
| Sanofi-aventis U.S. LLCMultaq | $142 | $20,79617 claims |
| Novo NordiskOzempic | $164 | $14,41414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Palm Coast
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.